BOSTON, Mass. — The Board representing the founding investor group of Arena BioWorks announced that the research institute will be shut down due to ongoing adverse macroeconomic conditions affecting the biotech sector.
The group said market conditions have shifted significantly since Arena BioWorks was established, with weakened funding environments, policy uncertainty, and no clear indication of near-term improvement. Based on these factors, the investors unanimously determined that dissolving the organization is the most responsible course of action.
Arena’s scientific team plans to continue advancing the most promising programs developed at the institute, including therapeutic work in oncology, immune disorders, and brain health, through new avenues outside of Arena BioWorks.
The investor group said it intends to support employees through the transition by providing severance packages designed to offer sufficient time to secure new roles and maintain benefits.
Founded in 2024, Arena BioWorks is a privately funded biomedical research institute focused on accelerating the development of new medicines by integrating drug discovery and company creation. The institute applied artificial intelligence, disease mechanism research, and advanced technology to advance therapeutic candidates in brain health, oncology, and immunology.
